Delivery Order SPE2DB20D1109-SPE2DB22FN76U
- Not listed
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Telmisartan 40 mg tablets. The contract, valued at $9,841.85, was awarded on March 4, 2022, with a completion date of March 7, 2022. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which...
- This federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Telmisartan 40 mg tablets. The firm-fixed-price contract, valued at $1,103.80, has a completion date of January 23, 2023. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive...
- This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Telmisartan 40 mg tablets, a cardiovascular medication, with a ceiling value of $1,757.27 and a period of performance through October 16, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This is a delivery order under a larger Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Telmisartan 40 mg tablets. The total ceiling value of this delivery order is $1,564.76, with a completion date of November 8, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is registered in the System for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Telmisartan 40 mg tablets. The contract, valued at $31,017.60, is a firm fixed-price delivery order with a completion date of September 1, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,851.20 firm fixed-price contract is for the delivery of Telmisartan 40 mg tablets to support military healthcare programs. The contract has an ultimate completion date of January 15, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Telmisartan 40 mg tablets. The contract has a firm-fixed price of $1,355.12 and an ultimate completion date of August 21, 2024. AmerisourceBergen has been awarded this delivery order as part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025, which enables...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,336.61, is for the delivery of Telmisartan 40 mg tablets. It is a firm-fixed-price delivery order contract with a completion date of February 8, 2024. The contract is not designated under any set-aside program. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999...
- This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,074.01, is for the delivery of Telmisartan 40 mg tablets and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which serves as a primary...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Telmisartan 40 mg tablets. The contract has a total ceiling value of $40,017.75 and a completion date of October 21, 2024. It is a firm-fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB22FN76UDelivery Order
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Telmisartan 40 mg tablets, a cardiovascular medication, with a ceiling value of $3,068.85. The contract was awarded on March 9, 2022, with a completion date of March 10, 2022, and was not set aside for any specific business type. AmerisourceBergen Drug Corp, as a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a smaller IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 3/9/22 |